Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

THE ONE STUDY

Financiado

Cerrado

A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplan...

A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation Preventing immunological rejection of transplanted organs without the need for long-term use of pharmacological immunosuppression is a primary objective in transplantation medicine. Reducing the need for immunosuppression would dr... ver más

31/10/2017

KLINIKUM DER UNIVE...

15M€

Presupuesto del proyecto: 15M€

Líder del proyecto

KLINIKUM DER UNIVERSITAET REGENSBURG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 13 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-10-31 No tenemos la información de la convocatoria

0% 74% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

13 Participantes

KLINIKUM DER UNIVERSITAET RE...

0.00€ | Lider

KINGS COLLEGE LONDON

N.D. | Participante

ALTA SRLU

N.D. | Participante

UOXF

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ECP TOLERANCE An Investigation into Tolerance Induction by Extracorporeal... 45K€ Cerrado

CAR ART Chimeric Antigen Receptor to generate Alloantigen specific R... 171K€ Cerrado

SAF2016-80031-R MANIPULACION DE MACROFAGOS REGULADORES DURANTE TOLERANCIA A... 182K€ Cerrado

Allo-THYTECH Development and implementation in clinical practice of the a... 173K€ Cerrado

Smart ProTcell Smart Immune ProTcell: first-in-class allogeneic thymus empo... 4M€ Cerrado

SAF2013-48834-R ORIGEN, DESARROLLO, Y FUNCION IMMUNO REGULADORA DE CELULAS M... 163K€ Cerrado

Líder del proyecto

KLINIKUM DER UNIVERSITAET REGENSBURG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 15M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Preventing immunological rejection of transplanted organs without the need for long-term use of pharmacological immunosuppression is a primary objective in transplantation medicine. Reducing the need for immunosuppression would dramatically improve the outcome for transplant recipients and reduce health costs for society. The means to achieve this goal has not been realised with pharmacological or biological agents yet. Conditioning the immune response of solid organ transplant recipients towards allograft acceptance using cell-based therapies is now becoming technically feasible and clinically promising. The central focus of our proposed cooperative work programme is to produce distinct populations of haematopoietic regulatory cells and comparatively test their safety and efficacy in minimising pharmacological immunosuppression in solid organ transplantation. Preparations of regulatory T cells, macrophages and dendritic cells will be licensed for clinical manufacture in outstanding research facilities across Europe, and subsequently, these different tolerance-promoting cell types will be assessed in a single Phase I/II clinical study for safety, clinical practicality and efficacy. The therapeutic potential of these cells will be directly compared using one, single clinical protocol. In addition, we will study the tolerogenic characteristics of these regulatory cell types at in-depth molecular and functional levels. These integrative, but very focused, research plans are expected to result in the identification of the most promising regulatory cell products for further testing, and commercial exploitation: the final outcome is to identify a cell product which has genuine potential to induce operational tolerance if correctly applied in a Phase IIb clinical trial. This objective can only be accomplished by the cooperation of the most experienced researchers in this field across Europe, in alliance with SMEs devoted to cell therapy.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores